BSE - Delayed Quote INR

Alembic Pharmaceuticals Limited (APLLTD.BO)

901.70
+0.55
+(0.06%)
At close: 3:28:00 PM GMT+5:30
Loading Chart for APLLTD.BO
  • Previous Close 901.15
  • Open 904.95
  • Bid 902.15 x --
  • Ask 903.95 x --
  • Day's Range 877.95 - 905.55
  • 52 Week Range 725.60 - 1,296.15
  • Volume 3,491
  • Avg. Volume 7,065
  • Market Cap (intraday) 177.241B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) 30.41
  • EPS (TTM) 29.65
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield 11.00 (1.22%)
  • Ex-Dividend Date Jul 15, 2024
  • 1y Target Est 1,018.82

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

alembicpharmaceuticals.com

14,858

Full Time Employees

March 31

Fiscal Year Ends

Recent News: APLLTD.BO

View More

Performance Overview: APLLTD.BO

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

APLLTD.BO
15.27%
S&P BSE SENSEX (^BSESN)
1.68%

1-Year Return

APLLTD.BO
9.10%
S&P BSE SENSEX (^BSESN)
9.74%

3-Year Return

APLLTD.BO
27.67%
S&P BSE SENSEX (^BSESN)
45.87%

5-Year Return

APLLTD.BO
22.07%
S&P BSE SENSEX (^BSESN)
151.10%

Compare To: APLLTD.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: APLLTD.BO

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    177.13B

  • Enterprise Value

    188.69B

  • Trailing P/E

    30.36

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.65

  • Price/Book (mrq)

    3.41

  • Enterprise Value/Revenue

    2.83

  • Enterprise Value/EBITDA

    17.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.42%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    64.19B

  • Net Income Avi to Common (ttm)

    6.05B

  • Diluted EPS (ttm)

    29.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.29B

  • Total Debt/Equity (mrq)

    21.82%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: APLLTD.BO

View More

Company Insights: APLLTD.BO

Research Reports: APLLTD.BO

View More

People Also Watch